These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27799597)

  • 1. Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe.
    Achelrod D; Gray A; Preiss D; Mihaylova B
    Eur J Prev Cardiol; 2017 Mar; 24(4):426-436. PubMed ID: 27799597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions.
    Kotseva K; De Bacquer D; De Backer G; Rydén L; Jennings C; Gyberg V; Abreu A; Aguiar C; Conde AC; Davletov K; Dilic M; Dolzhenko M; Gaita D; Georgiev B; Gotcheva N; Lalic N; Laucevicius A; Lovic D; Mancas S; Miličić D; Oganov R; Pajak A; Pogosova N; Reiner Ž; Vulic D; Wood D; On Behalf Of The Euroaspire Investigators
    Eur J Prev Cardiol; 2016 Dec; 23(18):2007-2018. PubMed ID: 27638542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol complacency in Australia: time to revisit the basics of cardiovascular disease prevention.
    Carrington MJ; Retegan C; Johnston CI; Jennings GL; Stewart S
    J Clin Nurs; 2009 Mar; 18(5):678-86. PubMed ID: 19077020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
    BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptions.
    Senior V; Marteau TM; Weinman J;
    Cardiovasc Drugs Ther; 2004 Nov; 18(6):475-81. PubMed ID: 15770435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.
    Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC
    Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifestyle and psychosocial risk factors predict non-adherence to medication.
    Aggarwal B; Mosca L
    Ann Behav Med; 2010 Oct; 40(2):228-33. PubMed ID: 20668975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. For the majority of patients with diabetes blood pressure and lipid management is not in line with recommendations. Results from a large population-based cohort in Germany.
    Raum E; Lietzau S; Stegmaier C; Brenner H; Rothenbacher D
    Pharmacoepidemiol Drug Saf; 2008 May; 17(5):485-94. PubMed ID: 18383562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cholesterol-lowering drugs in the elderly. When to initiate, maintain or discontinue therapy?].
    Kleipool EEF; Dorresteijn JAN; Visseren FLJ; Hollander M; Peters MJL; Muller M
    Ned Tijdschr Geneeskd; 2018 Oct; 162():. PubMed ID: 30358363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
    Kushiro T; Mizuno K; Nakaya N; Ohashi Y; Tajima N; Teramoto T; Uchiyama S; Nakamura H;
    Hypertension; 2009 Feb; 53(2):135-41. PubMed ID: 19104004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China.
    Xia S; Du X; Guo L; Du J; Arnott C; Lam CSP; Huffman MD; Arima H; Yuan Y; Zheng Y; Wu S; Guang X; Zhou X; Lin H; Cheng X; Anderson CS; Dong J; Ma C
    Circulation; 2020 Feb; 141(7):530-539. PubMed ID: 32065775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003.
    Primatesta P; Poulter NR
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):292-8. PubMed ID: 16487439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
    Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
    Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
    Bangalore S; Fayyad R; Messerli FH; Laskey R; DeMicco DA; Kastelein JJ; Waters DD
    Am J Cardiol; 2017 Feb; 119(3):379-387. PubMed ID: 27939230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal and nonfatal cardiovascular disease and the use of therapies for secondary prevention in a rural region of India.
    Joshi R; Chow CK; Raju PK; Raju R; Reddy KS; Macmahon S; Lopez AD; Neal B
    Circulation; 2009 Apr; 119(14):1950-5. PubMed ID: 19332466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of cholesterol-lowering medications after coronary revascularization.
    Brophy JM; Bourgault C; Brassard P
    CMAJ; 2003 Nov; 169(11):1153-7. PubMed ID: 14638648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secular trends in cardiovascular disease risk factors according to body mass index in US adults.
    Gregg EW; Cheng YJ; Cadwell BL; Imperatore G; Williams DE; Flegal KM; Narayan KM; Williamson DF
    JAMA; 2005 Apr; 293(15):1868-74. PubMed ID: 15840861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
    Naderi SH; Bestwick JP; Wald DS
    Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.